Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1575-1585

  Gorzalka, Boris B ^a   Hill, Matthew N ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Antidepressant; Depression; Endocannabinoid

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CITALOPRAM; DRONABINOL; ENDOCANNABINOID; IMIPRAMINE; RIMONABANT; TRANYLCYPROMINE;

ANXIETY DISORDER; ARTICLE; CELL PROLIFERATION; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ELECTRIC SHOCK; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIFE STRESS; MONOAMINERGIC SYSTEM; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROCHEMISTRY; NEUROMODULATION; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN FUNCTION; PSYCHOPHARMACOLOGY; SIGNAL TRANSDUCTION;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER; ENDOCANNABINOIDS; HUMANS; SIGNAL TRANSDUCTION;

EID: 79961129713     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.11.021     Document Type: Article

References (195)

1. Adamczyk P., Golda A., McCreary A.C., Filip M., Przegalinski E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol 2008, 59:217-228.
2. Aguado T., Monory K., Palazuelos J., Stella N., Cravatt B., Lutz B., et al. The endocannabinoid system drives neural progenitor proliferation. FASEB J 2005, 19:1704-1706.
3. Ahn K., McKinney M.K., Cravatt B.F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008, 108:1687-1707.
4. Alonso R., Griebel G., Pavone G., Stemmelin J., Le Fur G., Soubrie P. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Mol Psychiatry 2004, 9:278-286. 224.
5. Ambrogini P., Orsini L., Mancini C., Ferri P., Barbanti I., Cuppini R. Persistently high corticosterone levels but not normal circadian fluctuations of the hormone affect cell proliferation in the adult rat dentate gyrus. Neuroendocrinology 2002, 76:366-372.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC; 2000.
7. Aso E., Ozaita A., Valdizan E.M., Ledent C., Pazos A., Maldonado R., et al. BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. J Neurochem 2008, 105:565-572.
8. Aso E., Renoir T., Mengod G., Ledent C., Hamon M., Maldonado R., et al. Lack of CB(1) receptor activity impairs serotonergic negative feedback. J Neurochem 2009, 109:935-944.
9. Aubry J.M., Pozzoli G., Vale W.W. Chronic treatment with the antidepressant amitriptyline decreases CRF-R1 receptor mRNA levels in the rat amygdala. Neurosci Lett 1999, 266:197-200.
10. Bambico F.R., Katz N., Debonnel G., Gobbi G. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 2007, 27:11700-11711.
11. Bambico F.R., Cassano T., Dominguez-Lopez S., Katz N., Walker C.D., Piomelli D., et al. Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology 2010, 35:2083-2100.
12. Banerjee S.P., Snyder S.H., Mechoulam R. Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. J Pharmacol Exp Ther 1975, 194:74-81.
13. Barden N., Reul J.M., Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?. Trends Neurosci 1995, 18:6-11.
14. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
15. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernandez-Ruiz J.J., et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 1999, 256:377-380.
16. Bisogno T., Melck D., Bobrov M., Gretskaya N.M., Bezuglov V.V., De Petrocellis L., et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000, 351(Pt 3):817-824.
17. Bissette G., Klimek V., Pan J., Stockmeier C., Ordway G. Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology 2003, 28:1328-1335.
18. Blumenthal J.A., Babyak M.A., Doraiswamy P.M., Watkins L., Hoffman B.M., Barbour K.A., et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med 2007, 69:587-596.
19. Bortolato M., Mangieri R.A., Fu J., Kim J.H., Arguello O., Duranti A., et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007, 62:1103-1110.
20. Brady L.S., Whitfield H.J., Fox R.J., Gold P.W., Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 1991, 87:831-837.
21. Brady L.S., Gold P.W., Herkenham M., Lynn A.B., Whitfield H.J. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 1992, 572:117-125.
22. Budziszewska B. Effect of antidepressant drugs on the hypothalamic-pituitary-adrenal axis activity and glucocorticoid receptor function. Pol J Pharmacol 2002, 54:343-349.
23. Budziszewska B., Siwanowicz J., Przegalinski E. The effect of chronic treatment with antidepressant drugs on the corticosteroid receptor levels in the rat hippocampus. Pol J Pharmacol 1994, 46:147-152.
24. Campbell S., Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 2004, 29:417-426.
25. Catalan R., Gallart J.M., Castellanos J.M., Galard R. Plasma corticotropin-releasing factor in depressive disorders. Biol Psychiatry 1998, 44:15-20.
26. Chen C., Bazan N.G. Lipid signaling: sleep, synaptic plasticity, and neuroprotection. Prostaglandins Other Lipid Mediat 2005, 77:65-76.
27. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
28. Connor T.J., Kelliher P., Shen Y., Harkin A., Kelly J.P., Leonard B.E. Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test. Pharmacol Biochem Behav 2000, 65:591-597.
29. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423-431.
30. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001, 98:9371-9376.
31. Czeh B., Michaelis T., Watanabe T., Frahm J., de Biurrun G., van Kampen M., et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 2001, 98:12796-12801.
32. Denson T.F., Earleywine M. Decreased depression in marijuana users. Addict Behav 2006, 31:738-742.
33. Derkinderen P., Valjent E., Toutant M., Corvol J.C., Enslen H., Ledent C., et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 2003, 23:2371-2382.
34. Deutsch D.G., Ueda N., Yamamoto S. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot Essent Fatty Acids 2002, 66:201-210.
35. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
36. Di Marzo V., Gobbi G., Szallasi A. Brain TRPV1: a depressing TR(i)P down memory lane?. Trends Pharmacol Sci 2008, 29:594-600.
37. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002, 99:10819-10824.
38. Domschke K., Dannlowski U., Ohrmann P., Lawford B., Bauer J., Kugel H., et al. Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 2008, 18:751-759.
39. D'Sa C., Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord 2002, 4:183-194.
40. Dubreucq S., Koehl M., Abrous D.N., Marsicano G., Chaouloff F. CB1 receptor deficiency decreases wheel-running activity: consequences on emotional behaviours and hippocampal neurogenesis. Exp Neurol 2010, 224:106-113.
41. Dunn A.L., Trivedi M.H., Kampert J.B., Clark C.G., Chambliss H.O. Exercise treatment for depression: efficacy and dose response. Am J Prev Med 2005, 28:1-8.
42. El-Alfy A.T., Ivey K., Robinson K., Ahmed S., Radwan M., Slade D., et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav 2010, 95:434-442.
43. Engin E., Treit D. The role of hippocampus in anxiety: intracerebral infusion studies. Behav Pharmacol 2007, 18:365-374.
44. Fadda P., Pani L., Porcella A., Fratta W. Chronic imipramine, l-sulpiride and mianserin decrease corticotropin releasing factor levels in the rat brain. Neurosci Lett 1995, 192:121-123.
45. Felder C.C., Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 1998, 38:179-200.
46. Fisar Z. Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol 2010, 381:563-572.
47. Frank E., Thase M.E. Natural history and preventative treatment of recurrent mood disorders. Annu Rev Med 1999, 50:453-468.
48. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003, 83:1017-1066.
49. Galea L.A., McEwen B.S., Tanapat P., Deak T., Spencer R.L., Dhabhar F.S. Sex differences in dendritic atrophy of CA3 pyramidal neurons in response to chronic restraint stress. Neuroscience 1997, 81:689-697.
50. Garcia-Gutierrez M.S., Perez-Ortiz J.M., Gutierrez-Adan A., Manzanares J. Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol 2010, 160:1773-1784.
51. Giedke H., Schwarzler F. Therapeutic use of sleep deprivation in depression. Sleep Med Rev 2002, 6:361-377.
52. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005, 102:18620-18625.
53. Gobshtis N., Ben-Shabat S., Fride E. Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness. Eur J Pharmacol 2007, 554:155-163.
54. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006, 1071:10-23.
55. Gorzalka B.B., Hill M.N., Hillard C.J. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev 2008, 32:1152-1160.
56. Gorzalka B.B., Hill M.N., Chang S.C. Male-female differences in the effects of cannabinoids on sexual behavior and gonadal hormone function. Horm Behav 2010, 58:91-99.
57. Gruber A.J., Pope H.G., Brown M.E. Do patients use marijuana as an antidepressant?. Depression 1996, 4:77-80.
58. Haller J., Bakos N., Szirmay M., Ledent C., Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002, 16:1395-1398.
59. Haller J., Varga B., Ledent C., Barna I., Freund T.F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 2004, 19:1906-1912.
60. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001, 98:3662-3665.
61. Healy D.G., Harkin A., Cryan J.F., Kelly J.P., Leonard B.E. Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacology (Berl) 1999, 145:303-308.
62. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
63. Herman J.P., Mueller N.K. Role of the ventral subiculum in stress integration. Behav Brain Res 2006, 174:215-224.
64. Hesketh S.A., Brennan A.K., Jessop D.S., Finn D.P. Effects of chronic treatment with citalopram on cannabinoid and opioid receptor-mediated G-protein coupling in discrete rat brain regions. Psychopharmacology (Berl) 2008, 198:29-36.
65. Hill M.N., Gorzalka B.B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behav Pharmacol 2005, 16:333-352.
66. Hill M.N., Gorzalka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005, 15:593-599.
67. Hill M.N., Gorzalka B.B. Impairments in endocannabinoid signaling and depressive illness. JAMA 2009, 301:1165-1166.
68. Hill M.N., Patel S., Carrier E.J., Rademacher D.J., Ormerod B.K., Hillard C.J., et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005, 30:508-515.
69. Hill M.N., Ho W.S., Sinopoli K.J., Viau V., Hillard C.J., Gorzalka B.B. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 2006, 31:2591-2599.
70. Hill M.N., Kambo J.S., Sun J.C., Gorzalka B.B., Galea L.A. Endocannabinoids modulate stress-induced suppression of hippocampal cell proliferation and activation of defensive behaviours. Eur J Neurosci 2006, 24:1845-1849.
71. Hill M.N., Barr A.M., Ho W.S., Carrier E.J., Gorzalka B.B., Hillard C.J. Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. J Neurochem 2007, 103:47-56.
72. Hill M.N., Karacabeyli E.S., Gorzalka B.B. Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 2007, 32:350-357.
73. Hill M.N., Carrier E.J., McLaughlin R.J., Morrish A.C., Meier S.E., Hillard C.J., et al. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 2008, 106:2322-2336.
74. Hill M.N., Ho W.S., Hillard C.J., Gorzalka B.B. Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. J Neural Transm 2008, 115:1673-1679.
75. Hill M.N., Miller G.E., Ho W.S., Gorzalka B.B., Hillard C.J. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008, 41:48-53.
76. Hill M.N., Miller G.E., Carrier E.J., Gorzalka B.B., Hillard C.J. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 2009, 34:1257-1262.
77. Hill M.N., McLaughlin R.J., Bingham B., Shrestha L., Lee T.T., Gray J.M., et al. Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci USA 2010, 107:9406-9411.
78. Hill M.N., Titterness A.K., Morrish A.C., Carrier E.J., Lee T.T., Gil-Mohapel J., et al. Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus. Hippocampus 2010, 20:513-523.
79. Hillard C.J. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat 2000, 61:3-18.
80. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
81. Horder J., Cowen P.J., Di Simplicio M., Browning M., Harmer C.J. Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology (Berl) 2009, 205:85-91.
82. Horder J., Harmer C.J., Cowen P.J., McCabe C. Reduced neural response to reward following 7days treatment with the cannabinoid CB(1) antagonist rimonabant in healthy volunteers. Int J Neuropsychopharmacol 2010, 13:1103-1113.
83. Howlett A.C. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002, 68-69:619-631.
84. Howlett A.C., Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids 2000, 108:53-70.
85. Hu B., Doods H., Treede R.D., Ceci A. Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain 2009, 143:206-212.
86. Huestis M.A., Gorelick D.A., Heishman S.J., Preston K.L., Nelson R.A., Moolchan E.T., et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001, 58:322-328.
87. Jayatissa M.N., Bisgaard C., Tingstrom A., Papp M., Wiborg O. Hippocampal cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of depression. Neuropsychopharmacology 2006, 31:2395-2404.
88. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.P., Bai G., et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005, 115:3104-3116.
89. Juhasz G., Chase D., Pegg E., Downey D., Toth Z.G., Stones K., et al. CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology 2009, 34:2019-2027.
90. Kamprath K., Marsicano G., Tang J., Monory K., Bisogno T., Di Marzo V., et al. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci 2006, 26:6677-6686.
91. Keilhoff G., Becker A., Grecksch G., Bernstein H.G., Wolf G. Cell proliferation is influenced by bulbectomy and normalized by imipramine treatment in a region-specific manner. Neuropsychopharmacology 2006, 31:1165-1176.
92. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8-19.
93. Kim J., Alger B.E. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci 2004, 7:697-698.
94. Korte S.M., De Kloet E.R., Buwalda B., Bouman S.D., Bohus B. Antisense to the glucocorticoid receptor in hippocampal dentate gyrus reduces immobility in forced swim test. Eur J Pharmacol 1996, 301:19-25.
95. Kozak K.R., Rowlinson S.W., Marnett L.J. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 2000, 275:33744-33749.
96. Liu J., Wang L., Harvey-White J., Osei-Hyiaman D., Razdan R., Gong Q., et al. A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA 2006, 103:13345-13350.
97. Lopez-Munoz F., Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009, 15:1563-1586.
98. Malberg J.E., Blendy J.A. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci 2005, 26:631-638.
99. Malberg J.E., Duman R.S. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology 2003, 28:1562-1571.
100. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000, 20:9104-9110.
101. Marchalant Y., Brothers H.M., Wenk G.L. Cannabinoid agonist WIN-55, 212-2 partially restores neurogenesis in the aged rat brain. Mol Psychiatry 2009, 14:1068-1069.
102. Marrs W.R., Blankman J.L., Horne E.A., Thomazeau A., Lin Y.H., Coy J., et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 2010, 13:951-957.
103. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
104. Mato S., Vidal R., Castro E., Diaz A., Pazos A., Valdizan E.M. Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine 1A receptor-dependent mechanisms. Mol Pharmacol 2010, 77:424-434.
105. Mazor M., Dvilansky A., Aharon M., Lazarovitz Z., Nathan I. Effect of cannabinoids on the activity of monoamine oxidase in normal human platelets. Arch Int Physiol Biochim 1982, 90:15-20.
106. McEwen B.S. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 2005, 54:20-23.
107. McKenna M.T., Michaud C.M., Murray C.J., Marks J.S. Assessing the burden of disease in the United States using disability-adjusted life years. Am J Prev Med 2005, 28:415-423.
108. McKinnon M.C., Yucel K., Nazarov A., MacQueen G.M. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 2009, 34:41-54.
109. McLaughlin R.J., Hill M.N., Morrish A.C., Gorzalka B.B. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect. Behav Pharmacol 2007, 18:431-438.
110. Mendiguren A., Pineda J. Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats. Eur J Pharmacol 2006, 534:83-88.
111. Meston C.M., Gorzalka B.B. Psychoactive drugs and human sexual behavior: the role of serotonergic activity. J Psychoactive Drugs 1992, 24:1-40.
112. Mikics E., Vas J., Aliczki M., Halasz J., Haller J. Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission. Behav Pharmacol 2009, 20:265-272.
113. Moldrich G., Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 2000, 21:1735-1742.
114. Monteleone P., Bifulco M., Maina G., Tortorella A., Gazzerro P., Proto M.C., et al. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res 2010, 61:400-404.
115. Montgomery S.A., Baldwin D.S., Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord 2002, 69:119-140.
116. Morrish A.C., Hill M.N., Riebe C.J., Gorzalka B.B. Protracted cannabinoid administration elicits antidepressant behavioral responses in rats: role of gender and noradrenergic transmission. Physiol Behav 2009, 98:118-124.
117. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
118. Murphy B.E. Steroids and depression. J Steroid Biochem Mol Biol 1991, 38:537-559.
119. Murphy B.E. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 1997, 22(Suppl 1):S125-S132.
120. Nakagawa S., Kim J.E., Lee R., Malberg J.E., Chen J., Steffen C., et al. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J Neurosci 2002, 22:3673-3682.
121. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984, 226:1342-1344.
122. Nemeroff C.B., Owens M.J., Bissette G., Andorn A.C., Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988, 45:577-579.
123. Nissen S.E., Nicholls S.J., Wolski K., Rodes-Cabau J., Cannon C.P., Deanfield J.E., et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008, 299:1547-1560.
124. Nunez E., Benito C., Pazos M.R., Barbachano A., Fajardo O., Gonzalez S., et al. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 2004, 53:208-213.
125. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001, 29:729-738.
126. Okamoto Y., Morishita J., Tsuboi K., Tonai T., Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 2004, 279:5298-5305.
127. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Meozzi P.A., Myers L., et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS ONE 2008, 3:e1640.
128. Overstreet D.H., Griebel G. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 2004, 497:49-53.
129. Palazzo E., de Novellis V., Petrosino S., Marabese I., Vita D., Giordano C., et al. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. Eur J Neurosci 2006, 24:2011-2020.
130. Parker K.J., Schatzberg A.F., Lyons D.M. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav 2003, 43:60-66.
131. Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci 1999, 65:637-644.
132. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., Hillard C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004, 145:5431-5438.
133. Patel S., Roelke C.T., Rademacher D.J., Hillard C.J. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci 2005, 21:1057-1069.
134. Patel S., Kingsley P.J., Mackie K., Marnett L.J., Winder D.G. Repeated homotypic stress elevates 2-arachidonoylglycerol levels and enhances short-term endocannabinoid signaling at inhibitory synapses in basolateral amygdala. Neuropsychopharmacology 2009, 34:2699-2709.
135. Pepin M.C., Beaulieu S., Barden N. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res Mol Brain Res 1989, 6:77-83.
136. Phillips M.L., Drevets W.C., Rauch S.L., Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry 2003, 54:515-528.
137. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003, 4:873-884.
138. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
139. Plendl W., Wotjak C.T. Dissociation of within- and between-session extinction of conditioned fear. J Neurosci 2010, 30:4990-4998.
140. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002, 301:1020-1024.
141. Przegalinski E., Budziszewska B., Siwanowicz J., Jaworska L. The effect of repeated combined treatment with nifedipine and antidepressant drugs or electroconvulsive shock on the hippocampal corticosteroid receptors in rats. Neuropharmacology 1993, 32:1397-1400.
142. Rademacher D.J., Hillard C.J. Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:633-641.
143. Rademacher D.J., Meier S.E., Shi L., Ho W.S., Jarrahian A., Hillard C.J. Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 2008, 54:108-116.
144. Ravinet Trillou C., Delgorge C., Menet C., Arnone M., Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004, 28:640-648.
145. Reich C.G., Taylor M.E., McCarthy M.M. Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats. Behav Brain Res 2009, 203:264-269.
146. Ressler K.J., Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000, 12(Suppl 1):2-19.
147. Reul J.M., Stec I., Soder M., Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993, 133:312-320.
148. Reul J.M., Labeur M.S., Grigoriadis D.E., De Souza E.B., Holsboer F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 1994, 60:509-519.
149. Rodriguez-Gaztelumendi A., Rojo M.L., Pazos A., Diaz A. Altered CB receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine. J Neurochem 2009, 108:1423-1433.
150. Rossi S., De Chiara V., Musella A., Kusayanagi H., Mataluni G., Bernardi G., et al. Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum. J Neurosci 2008, 28:7284-7292.
151. Rubino T., Parolaro D. Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol 2008, 286:S108-S113.
152. Ruhe H.G., Mason N.S., Schene A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007, 12:331-359.
153. Rutkowska M., Jachimczuk O. Antidepressant-like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors. Acta Pol Pharm 2004, 61:165-167.
154. Saarelainen T., Hendolin P., Lucas G., Koponen E., Sairanen M., MacDonald E., et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003, 23:349-357.
155. Sanchis-Segura C., Cline B.H., Marsicano G., Lutz B., Spanagel R. Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berl) 2004, 176:223-232.
156. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
157. Santucci V., Storme J.J., Soubrie P., Le Fur G. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 1996, 58:PL103-PL110.
158. Schatzberg A.F. Pharmacological principles of antidepressant efficacy. Hum Psychopharmacol 2002, 17(Suppl 1):S17-S22.
159. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965, 122:509-522.
160. Schlicker E., Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001, 22:565-572.
161. Schurr A., Livne A. Differential inhibition of mitochondrial monoamine oxidase from brain by hashish components. Biochem Pharmacol 1976, 25:1201-1203.
162. Seckl J.R., Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992, 55:621-626.
163. Shearman L.P., Rosko K.M., Fleischer R., Wang J., Xu S., Tong X.S., et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003, 14:573-582.
164. Sheline Y.I., Sanghavi M., Mintun M.A., Gado M.H. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999, 19:5034-5043.
165. Sheline Y.I., Gado M.H., Kraemer H.C. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003, 160:1516-1518.
166. Silverstone P.H., Silverstone T. A review of acute treatments for bipolar depression. Int Clin Psychopharmacol 2004, 19:113-124.
167. Simon G.M., Cravatt B.F. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem 2006, 281:26465-26472.
168. Starkman M.N., Schteingart D.E., Schork M.A. Depressed mood and other psychiatric manifestations of Cushing's syndrome: relationship to hormone levels. Psychosom Med 1981, 43:3-18.
169. Steffens M., Feuerstein T.J. Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex-involvement of Na(+)/K(+)-ATPase. Neurochem Int 2004, 44:529-538.
170. Steiner M.A., Marsicano G., Nestler E.J., Holsboer F., Lutz B., Wotjak C.T. Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 2008, 33:54-67.
171. Steiner M.A., Marsicano G., Wotjak C.T., Lutz B. Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses. Psychoneuroendocrinology 2008, 33:1165-1170.
172. Steiner M.A., Wanisch K., Monory K., Marsicano G., Borroni E., Bachli H., et al. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. Pharmacogenomics J 2008, 8:196-208.
173. Stillman R.C., Wyatt R.J., Murphy D.L., Rauscher F.P. Low platelet monoamine oxidase activity and chronic marijuana use. Life Sci 1978, 23:1577-1581.
174. Sugiura T., Waku K. Cannabinoid receptors and their endogenous ligands. J Biochem 2002, 132:7-12.
175. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89-97.
176. Tardito D., Perez J., Tiraboschi E., Musazzi L., Racagni G., Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 2006, 58:115-134.
177. Thase M.E. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry 2003, 64(Suppl 13):18-25.
178. Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry 1993, 163:141-149.
179. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
180. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
181. Vaughn L.K., Denning G., Stuhr K.L., de Wit H., Hill M.N., Hillard C.J. Endocannabinoid signalling: has it got rhythm?. Br J Pharmacol 2010, 160:530-543.
182. Velenovska M., Fisar Z. Effect of cannabinoids on platelet serotonin uptake. Addict Biol 2007, 12:158-166.
183. Vida S., Looper K. Precision and comparability of adverse event rates of newer antidepressants. J Clin Psychopharmacol 1999, 19:416-426.
184. Wamsteeker J.I., Kuzmiski J.B., Bains J.S. Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus. J Neurosci 2010, 30:11188-11196.
185. Wang W., Sun D., Pan B., Roberts C.J., Sun X., Hillard C.J., et al. Deficiency in endocannabinoid signaling in the nucleus accumbens induced by chronic unpredictable stress. Neuropsychopharmacology 2010, 35:2249-2261.
186. Webster M.J., Knable M.B., O'Grady J., Orthmann J., Weickert C.S. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 2002, 7:924-994.
187. Widerlov E., Bissette G., Nemeroff C.B. Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients. J Affect Disord 1988, 14:99-107.
188. Wiley J.L., Burston J.J., Leggett D.C., Alekseeva O.O., Razdan R.K., Mahadevan A., et al. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 2005, 145:293-300.
189. Williamson E.M., Evans F.J. Cannabinoids in clinical practice. Drugs 2000, 60:1303-1314.
190. Wilson R.I., Kunos G., Nicoll R.A. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 2001, 31:453-462.
191. Wolf S.A., Bick-Sander A., Fabel K., Leal-Galicia P., Tauber S., Ramirez-Rodriguez G., et al. Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Commun Signal 2010, 8:12.
192. Wolkowitz O.M., Reus V.I. Treatment of depression with antiglucocorticoid drugs. Psychosom Med 1999, 61:698-711.
193. Wolkowitz O.M., Reus V.I., Chan T., Manfredi F., Raum W., Johnson R., et al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry 1999, 45:1070-1074.
194. Wong E.Y., Herbert J. The corticoid environment: a determining factor for neural progenitors' survival in the adult hippocampus. Eur J Neurosci 2004, 20:2491-2498.
195. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000, 34:171-181.